H37Rv and drug-resistant clinical isolates. Among them, two compounds 7a and 7b exhibited excellent activity against the three tested strains. Both of them were comparable to the first-line anti-TB agents INH and RIF against MTB H37Rv, and were far more potent than INH and RIF against MDR-TB 16833 and 16995 strains. Thus, both of them could act as leads for further optimization.
设计,合成了一系列
肟官能化的硝基
呋喃酰胺,并评估了它们对
MTB H37Rv和耐药临床分离株的体外抗分枝杆菌活性。其中,两种化合物7a和7b对三种测试菌株表现出优异的活性。它们两者均与针对
MTB H37Rv的一线抗结核病药物INH和RIF相当,并且比针对MDR-TB 16833和16995菌株的INH和RIF更有力。因此,它们两者都可以作为进一步优化的线索。